Investment Rating - The report upgrades the investment rating to "Strong Buy" based on expected revenue growth and strategic developments [5][8]. Core Insights - The company reported a revenue of 3.76 billion RMB for 2025, a year-on-year increase of 58%, driven by significant R&D investments [2][8]. - Adjusted operating loss for 2025 was 2.37 billion RMB, widening by 880 million RMB compared to the previous year [2]. - The company is positioned as a leading player in the mid-to-high-end intelligent driving market, with over 80% of its revenue coming from product solutions [8]. Financial Performance - Revenue projections for 2026, 2027, and 2028 are 5.99 billion RMB, 9.32 billion RMB, and 13.87 billion RMB, respectively, with year-on-year growth rates of 59.3%, 55.6%, and 48.9% [4]. - The net profit attributable to shareholders is expected to improve from a loss of 3.51 billion RMB in 2026 to a profit of 628 million RMB by 2028 [4]. - The gross margin for 2025 was 64.5%, a decrease of 13 percentage points year-on-year, attributed to changes in product mix and pricing strategies [8]. Market Position - The company achieved a market penetration rate of 42.6% in China's passenger car NOA (Navigation on Autopilot) segment, significantly increasing from 21.6% [8]. - In the market for vehicles priced below 200,000 RMB, the NOA penetration rate surged from 5% at the beginning of 2025 to over 50% by the end of the year [8]. - The company holds a 14.4% market share in the overall NOA market and 44.2% in the sub-200,000 RMB segment, marking it as a leader in the low-cost NOA niche [8]. Product Development and Future Outlook - The company plans to launch a new integrated vehicle intelligence chip and operating system in April, aiming to enhance user experience and reduce costs [8]. - The upcoming HSD 2.0 is expected to drive significant growth in orders, with a target of achieving a tenfold increase in MPI (Market Penetration Index) [8]. - The company has established partnerships with 11 OEMs for over 40 export models, reinforcing its international market presence [8]. Valuation - The target price range for the stock is set between 9.27 and 11.59 HKD, reflecting a potential upside of 30% to 63% from the current price of 7.12 HKD [5][8].

Investment Rating - The report maintains a "Buy" rating for China Foods (0506) [2][6]. Core Insights - The company has shown stable revenue growth over the past 25 years and is expected to continue this trend into 2026, benefiting from efficiency improvements that offset some raw material cost pressures [2]. - The company achieved a revenue of 22,070 million RMB in 2025, reflecting a year-over-year increase of 2.7%, with a volume growth of 2.8% [10]. - The gross profit margin decreased by 0.71 percentage points to 37.08% due to a higher proportion of lower-margin water products and fluctuating aluminum prices [10]. - The net profit for 2025 was 861 million RMB, a slight increase of 0.17% year-over-year, with a net profit margin of 3.91% [10]. Financial Summary - Total revenue projections for the upcoming years are as follows: - 2024: 21,492 million RMB - 2025: 22,070 million RMB - 2026: 22,849 million RMB - 2027: 23,543 million RMB - 2028: 24,195 million RMB [4]. - The net profit projections are: - 2024: 861 million RMB - 2025: 862 million RMB - 2026: 897 million RMB - 2027: 944 million RMB - 2028: 974 million RMB [4]. - The company’s PE ratio is projected to decrease from 12.55 in 2024 to 11.08 in 2028, indicating a potential increase in valuation attractiveness [4]. Segment Performance - The beverage categories showed varied performance: - Soft drinks generated revenue of 16,685 million RMB, with stable sales and a market share close to 60% [10]. - Juice revenue was 3,028 million RMB, reflecting a decline of 3.37% year-over-year [10]. - Water sales reached 929 million RMB, with a growth of 4.28% year-over-year [10]. - Functional beverages saw significant growth, with sales of 320 million RMB, up 28.07% year-over-year [10]. Strategic Outlook - The company continues to focus on a "restructuring" strategy, enhancing product quality, optimizing channel structures, and improving digital marketing and supply chain capabilities [10]. - The report anticipates that the company will maintain steady and high-quality development moving forward [10].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of 82.26 HKD [7][11]. Core Insights - The company is expected to achieve significant growth in 2025, with revenue, net profit, and adjusted net profit projected at 5.944 billion, 1.480 billion, and 1.559 billion RMB respectively, representing year-on-year increases of 46.69%, 38.41%, and 69.93% [1][10]. - The company has a strong order pipeline, with new contracts signed in 2025 amounting to 1.33 billion USD, a 41% increase year-on-year, and a backlog of 1.49 billion USD, up 50% year-on-year [2]. - The company is expanding its production capacity through both self-built facilities and acquisitions, enhancing its global leadership position in the industry [3]. Summary by Sections Financial Performance - In 2025, the company achieved a gross margin of 36.0%, an increase of 5.4 percentage points year-on-year, indicating strong operational efficiency [4]. - The company’s sales, management, and R&D expenses for 2025 were 1.09 billion, 2.25 billion, and 1.47 billion RMB respectively, with corresponding expense ratios of 1.8%, 3.8%, and 2.5% [4]. Capacity Expansion - The company is set to double its DP capacity by 2029, with several new production lines expected to come online between 2026 and 2028 [3]. - The acquisition of Dongyao Pharmaceuticals adds significant production capabilities, including two antibody production lines and three ADC production workshops [3]. Profitability Forecast - Adjusted net profit forecasts for 2026 and 2027 have been revised to 2.11 billion and 2.87 billion RMB, reflecting a compound annual growth rate (CAGR) of 35% from 2025 to 2027 [5][11]. - The expected earnings per share (EPS) for 2026 and 2027 are projected at 1.68 and 2.28 RMB respectively [10][11].

证券研究报告 港股通 中国金茂 (817 HK) 盈利能力逆势改善 | 华泰研究 | | | 年报点评 | 投资评级(维持): | 增持 | | --- | --- | --- | --- | --- | --- | | 2026 年 | 3 月 | 24 日│中国香港 | 房地产开发 | 目标价(港币): | 1.60 | 公司公布 25 年业绩：收入 593.7 亿元，同比+0.5%；归母净利润 12.5 亿元， 同比+18%，归母净利润增速略低于我们预期（全年同比+21%），主要因 应占合营公司损益低于我们预期。25 年公司开发业务销售额逆势实现增长， 24 年以来新获取项目的利润兑现度较高且 25 年毛利率有所提升。同时，公 司有序推进存量盘活工作，计划在三年内解决 80%的存量问题，25 年已完 成 36%，后续资产结构的持续优化值得期待。维持"增持"评级。 开发业务盈利边际改善，第二增长曲线稳健增长 公司 25 年物业开发结转收入同比+0.6%，结转毛利率同比+2pct 至 13%， 开发业务盈利边际修复。公司 24 年以来获取新项目 43 个，平均销售净利 率超 10%，后续随着高利润新项目结转 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 576.70 [5][4] Core Insights - The company reported a revenue of RMB 2.058 billion for 2025, representing a year-on-year growth of 6.5%, but incurred a loss of RMB 381.97 million [1] - The growth in revenue is attributed to the continued ramp-up of SKB264 sales and BD/R&D service income [1] - The company is expected to see significant growth in SKB264 sales, particularly with new indications entering the insurance reimbursement list [2] - The overseas phase III clinical data for SKB264 is anticipated to mature by the end of 2026, potentially contributing significantly to revenue [2] - The company is also optimistic about other pipeline products, particularly SKB571, which is expected to show strong efficacy with low systemic toxicity [3] Financial Projections - Revenue projections for 2026, 2027, and 2028 are RMB 2.702 billion, RMB 5.868 billion, and RMB 8.834 billion respectively, with significant growth rates expected [4][8] - The company is projected to turn profitable in 2027, with an estimated net profit of RMB 1.087 billion [8] - The DCF valuation method estimates the company's market value at HKD 134.5 billion [9]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 20 USD for US shares and 50 HKD for Hong Kong shares [6][4]. Core Insights - The company has demonstrated significant revenue growth, with Q4 2025 revenue reaching 314 million RMB, a year-on-year increase of 123%. The full-year revenue for 2025 was 680 million RMB, up 90% year-on-year [1]. - The company is focusing on improving unit economics (UE) for its Robotaxi business, which has seen a 210% year-on-year revenue increase, indicating strong market demand and operational efficiency [1][2]. - The company has a robust cash reserve of approximately 7.1 billion RMB, allowing for continued investment and expansion, including a planned buyback of 100 million USD by March 2027 [1][4]. Summary by Sections Financial Performance - Q4 2025 Non-GAAP net profit was -376 million RMB, with a Non-GAAP net profit margin of -120%, showing a 41 percentage point improvement from the previous quarter [1]. - The company expects to achieve breakeven in unit economics by 2026 and 2028 at the company level, reflecting a positive long-term outlook [22]. Market Expansion - The company has expanded its Robotaxi operations to 12 countries and over 40 cities, with successful deployments in major markets such as Abu Dhabi and Dubai [3][4]. - The company plans to deploy at least 1,200 Robotaxis in the Middle East by 2027, focusing on key urban areas [3]. Technological Advancements - The company has partnered with Bosch to develop advanced driver-assistance systems (ADAS), enhancing its competitive edge in the autonomous driving sector [2]. - The upgraded GXR platform has reduced vehicle costs by approximately 15% and improved sensor capabilities, indicating a commitment to technological innovation [2]. Revenue Projections - Revenue forecasts for 2026 and 2027 have been adjusted upward by 1.3% and 0.6%, respectively, with projected revenues of 1.023 billion RMB and 2.08 billion RMB [22][23]. - The company anticipates a significant increase in revenue to 7.185 billion RMB by 2028, driven by expanding market presence and operational efficiencies [22].

Investment Rating - The report maintains a "Strong Buy" rating for China Tower Corporation (00788.HK) [3] Core Insights - In 2025, the company achieved a revenue of RMB 100.41 billion, representing a year-on-year growth of 2.7%, while the profit attributable to shareholders was RMB 11.63 billion, up 8.4% year-on-year [1] - The company is focusing on a "one body, two wings" strategy, which has led to a diversified growth pattern, with the operator business generating revenue of RMB 84.73 billion, a 0.7% increase year-on-year, and the two wings business achieving a total revenue of RMB 14.99 billion, up 11.9% year-on-year [6] - The company is capitalizing on opportunities from digital transformation and green initiatives, with its smart connection business revenue exceeding RMB 10.17 billion, a 14.2% increase, and energy business revenue reaching RMB 4.81 billion, up 7.5% [6] Financial Performance - The company reported a net profit of RMB 11.63 billion for 2025, with a net cash flow from operating activities of RMB 56.12 billion, reflecting a 13.4% year-on-year increase [6] - The free cash flow saw a significant increase of 51.9% year-on-year, reaching RMB 26.63 billion, while the net debt leverage ratio decreased by 3.3 percentage points to 27.7% [6] - The dividend payout ratio increased by 1 percentage point to 77%, with a total dividend distribution of RMB 0.45789 per share (pre-tax) [6] Financial Projections - Revenue is projected to grow from RMB 97.77 billion in 2024 to RMB 111.77 billion by 2028, with a compound annual growth rate (CAGR) of approximately 4% [2] - The net profit is expected to increase from RMB 10.73 billion in 2024 to RMB 19.31 billion in 2028, with a CAGR of around 11% [2] - The earnings per share (EPS) is forecasted to rise from RMB 0.61 in 2024 to RMB 1.10 in 2028 [2] Key Financial Ratios - The return on equity (ROE) is projected to improve from 5.4% in 2024 to 8.7% in 2028 [8] - The asset-liability ratio is expected to decrease from 39.9% in 2024 to 32.9% in 2028, indicating improved financial stability [8] - The price-to-earnings (PE) ratio is forecasted to decline from 15.8 in 2024 to 8.8 in 2028, suggesting potential undervaluation [8]

Investment Rating - The report maintains a "BUY" rating for SenseTime, indicating a potential return of over 15% over the next 12 months [16]. Core Insights - SenseTime's FY25 results exceeded expectations, with total revenue growing by 33% YoY to RMB5.01 billion, driven by the strong performance of its Generative AI business [1][2]. - The adjusted net loss for FY25 narrowed by 54% YoY to RMB1.96 billion, outperforming the consensus estimate, primarily due to effective operating expense control [1]. - The company expects total revenue to grow by 27% YoY to RMB6.39 billion in FY26E, supported by a 35% YoY increase in Generative AI revenue [1][9]. - The target price has been raised to HK$2.50 based on a 12x FY26E EV/sales multiple, reflecting the company's leadership in China's Generative AI cloud services market [3][11]. Financial Performance - FY25 revenue from the Generative AI business increased by 51% YoY to RMB3.63 billion, accounting for 72% of total revenue [8]. - The Computer Vision business revenue grew by 3% YoY to RMB1.08 billion, driven by overseas market growth and domestic demand recovery [8]. - The adjusted net margin improved by 75 basis points YoY to -39% in FY25, supported by operating leverage and a reduction in operating expenses by 11% YoY [8]. Revenue Forecasts - Revenue projections for FY26E and FY27E have been revised upwards by 3-6%, with expected revenues of RMB6.39 billion and RMB7.68 billion respectively [1][9]. - The report anticipates a breakeven on adjusted EBITDA level in FY26E, with adjusted net loss expected to narrow by 66% YoY [8]. Valuation - SenseTime is valued at US$2.50 per share based on a 12x FY26E EV/sales, which is at a premium to the sector average of 5x [11].

Investment Rating - The report maintains a "BUY" rating for Kelun-Biotech, indicating a potential return of over 15% over the next 12 months [3][14]. Core Insights - Kelun-Biotech is transitioning from a clinical-stage biotech to a biopharmaceutical company, with 2025 marked as its inaugural year of commercialization, supported by four approved products and a strong revenue trajectory [1]. - The company reported total revenue of RMB2.06 billion in 2025, reflecting a year-on-year growth of 6.5%, with pharmaceutical product sales contributing RMB543 million [1][2]. - The inclusion of three core assets (Sac-TMT, A167, and A140) in the National Reimbursement Drug List (NRDL) effective January 2026 is expected to drive volume growth in 2026 [1]. - Despite a widened net loss of RMB382 million in 2025, the company's financial position remains robust, with RMB4.6 billion in cash and financial assets as of the end of 2025 [1]. Financial Summary - Revenue projections for FY26E are RMB2.127 billion, with expected growth of 3.4% year-on-year, and projected revenue for FY28E is RMB5.866 billion, reflecting a significant growth of 113.6% [2][11]. - The net profit is projected to be a loss of RMB689.7 million in FY26E, improving to a profit of RMB703.6 million by FY28E [2][11]. - The report indicates a gross profit margin improvement from 71.9% in FY25A to 81.6% in FY28E [12]. Share Performance and Valuation - The target price for Kelun-Biotech is set at HK$507.11, representing a 20.5% upside from the current price of HK$421.00 [3]. - The market capitalization of the company is approximately HK$98.17 billion [3]. - The DCF valuation per share is estimated at RMB446.25, equivalent to HK$507.11, based on a WACC of 8.69% and a terminal growth rate of 3.5% [7].

Investment Rating - The report maintains a "BUY" rating for WuXi XDC, indicating a potential return of over 15% over the next 12 months [17]. Core Insights - WuXi XDC reported a robust 46.7% year-over-year increase in revenue for 2025, with adjusted attributable net profit growing by 69.9% year-over-year [1]. - The company's backlog surged by 50.3% year-over-year to reach US$1.49 billion, with newly signed orders growing by 41% year-over-year to US$1.33 billion, indicating strong growth momentum [1]. - Management anticipates revenue growth of more than 40% year-over-year in 2026, with gross profit margin expected to remain flat compared to 2025 [1]. - The company signed a record-breaking 70 new iCMC projects in 2025, up 32% year-over-year, reflecting strong demand from both Chinese and US clients [8]. - WuXi XDC plans to invest a total of RMB 8.0 billion in capital expenditures between 2026 and 2030, with RMB 3.1 billion projected for 2026 alone, representing a 158% year-over-year increase over 2025 [8]. - The target price has been adjusted from HK$88.00 to HK$82.00, reflecting updated guidance and forecasts [3][8]. Financial Summary - For FY25, revenue was reported at RMB 5,944 million, with a year-over-year growth of 46.7% [2]. - Adjusted net profit for FY25 was RMB 1,559 million, reflecting a year-over-year growth of 69.9% [2]. - The projected revenue for FY26 is RMB 8,096 million, with a year-over-year growth of 36.2% [2]. - The adjusted net profit for FY26 is projected to be RMB 2,096 million, with a year-over-year growth of 34.5% [2]. - The company’s gross profit margin for FY25 was 36.0%, with expectations of maintaining similar margins in the following years [15].